<DOC>
	<DOCNO>NCT02322320</DOCNO>
	<brief_summary>This study design compare long-term outcome among patient randomize BMT CTN 0702 protocol ( NCT01109004 ) , `` A Trial Single Autologous Transplant without Consolidation Therapy versus Tandem Autologous Transplant Lenalidomide Maintenance Patients Multiple Myeloma '' . It hypothesize use novel anti-myeloma agent improve long-term progression-free survival ( PFS ) high-dose melphalan follow autologous hematopoietic cell transplantation ( HCT ) compare second autologous transplantation .</brief_summary>
	<brief_title>Continued , Long-Term Follow-Up Lenalidomide Maintenance Therapy Patients BMT CTN 0702 Protocol ( BMT CTN 07LT )</brief_title>
	<detailed_description>This study design compare long-term outcome among patient randomize BMT CTN 0702 protocol ( NCT01109004 ) . All patient consent follow death , progression , Second Primary Malignancies ( SPMs ) , Quality Life ( QOL ) . Patients consent long-term follow-up mechanism experience progression BMT CTN 0702 study follow standard Center International Blood Marrow Transplant Research ( CIBMTR ) long-term follow-up mechanism . Additionally , patient eligible willing continue lenalidomide maintenance therapy provide lenalidomide free charge . These patient continue receive lenalidomide maintenance therapy disease progression discontinuation due toxicity , death , withdrawal study . The endpoint assess include progression-free survival ( PFS ) , overall survival ( OS ) , event-free survival ( EFS ) , incidence second primary malignancy ( SPM ) health quality life ( QOL ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients fulfil follow criterion eligible provide continued longterm followup data part study : 1 . Enrolled randomized BMT CTN 0702 protocol . 2 . Alive completion BMT CTN 0702 protocol specify followup define 4 year postrandomization . 3 . Patients without evidence disease progression completion BMT CTN 0702 protocol specify follow . 4 . Signed Informed Consent Form . 5 . Patients ability speak English Spanish eligible participate HQL component trial . Inclusion Criteria Optional Longterm Lenalidomide Maintenance Therapy : Patients fulfil follow criterion eligible provide continued longterm followup data AND receive longterm lenalidomide maintenance therapy part study : 1 . Enrolled randomized BMT CTN 0702 . 2 . Completion 3 year maintenance therapy BMT CTN 0702 . 3 . Registered mandatory Revlimid REMS® program ( formerly RevAssist® Study Participants ( RASP ) program ) , willing able comply requirement Revlimid REMS® program , include counseling , pregnancy testing , phone survey . 4 . Signed informed consent form . 5 . Patients ability speak English Spanish eligible participate HQL component trial . Patients meet follow criterion ineligible receive longterm lenalidomide maintenance therapy part study : 1 . Patients evidence disease progression prior enrollment . 2 . Patients discontinue BMT CTN 0702 lenalidomide maintenance therapy , reason , prior completion 3 year 0702 maintenance . 3 . Female patient pregnant ( positive Beta Human Chorionic Gonadotropin ) breastfeeding . 4 . Females childbearing potential ( FCBP ) men sexual contact FCBP unwilling use contraceptive technique length lenalidomide maintenance therapy . 5 . Patients experience thromboembolic event full anticoagulation prior therapy lenalidomide . 6 . Patients unwilling take Deep Vein Thrombosis ( DVT ) prophylaxis . 7 . Patients develop second primary malignancy , exclude nonmelanoma skin cancer initiation lenalidomide maintenance therapy BMT CTN 0702 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Progression</keyword>
	<keyword>Long-term</keyword>
	<keyword>Anti-Myeloma Agents</keyword>
	<keyword>Hematologic Disorders</keyword>
</DOC>